A camptothecin analog for use in treatment of cancer, said analog having thefollowing structural formula:(see above formula)wherein R2 is methyl R3 is methyl and R1 is selected from the groupconsisting of:Vinyl, Chloromethyl, Iodomethyl, Acetomethyl, Hydroxymethyl,Thioacetoxymethyl,Hydroxypropyl, 3-benzenesulfonylpropyl, 3-imidazol-1-yl-propyl, 3-[1,2,4]triazol-1-yl-propyl3-dimethylaminopropyl, 3-(2-oxo-2H-pyridin-1-yl)-propyl, the phosphoric acidderivative (-(CH2)3-P(O)(OCH3)2), Propyl trifluoroacetamide, 3-phenylurea, 3,3-diethylurea,3,3-dimethylurea, [1,2,4]triazol-1-ylmethyl, 2-oxo-2H-pyridin-1-ylmethyl,pyrrolidin-1-ylmethyl, 1-methyl-1H-imidazol-2-ylsulfanylmethyl, 2-[4,5-dihydro-thiazol-2-ylsulfanylmethyl, 2-hydroxy-ethylsulfanylmethyl, 4-chlorobenzenesulfonamidomethyl,3-phenylurea, 3,3-diethylurea, 3,3-dimethylurea,and hydroxy, and pharmaceutically-acceptable salts thereof.
